Water Extract of Curcuma longa L. Ameliorates Non-Alcoholic Fatty Liver Disease

被引:68
|
作者
Mun, Jeongeun [1 ]
Kim, Shintae [1 ]
Yoon, Ho-Geun [2 ]
You, Yanghee [1 ]
Kim, Ok-Kyung [1 ]
Choi, Kyung-Chul [3 ]
Lee, Yoo-Hyun [4 ]
Lee, Jeongmin [5 ]
Park, Jeongjin [1 ]
Jun, Woojin [1 ]
机构
[1] Chonnam Natl Univ, Div Food & Nutr, Gwangju 61186, South Korea
[2] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 03722, South Korea
[3] Univ Ulsan, Dept Biomed Sci, Coll Med, Seoul 05505, South Korea
[4] Univ Suwon, Dept Food & Nutr, Gyeonggido 18323, South Korea
[5] Kyung Hee Univ, Dept Med Nutr, Gyeonggido 17104, South Korea
基金
新加坡国家研究基金会;
关键词
Curcuma longa L; non-alcoholic fatty liver disease; fatty acid uptake; lipid accumulation; oxidative stress; INDUCED OXIDATIVE STRESS; ANTIOXIDANT; DIET; EXPRESSION; PURIFICATION; GLUTATHIONE; RESISTANT; TRENDS; RATS;
D O I
10.3390/nu11102536
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Our aim was to investigate whether hot water extract (CLW) of Curcuma longa L. could prevent non-alcoholic fatty liver disease (NAFLD). HepG2 cells were treated with free fatty acid (FFA) mixture (oleic acid: palmitic acid, 2:1) for 24 h to stimulate in vitro fatty liver. In addition, C57BL/6 mice were fed 60 kcal% high-fat (HF) diet for eight weeks to induce fatty liver in vivo. Intracellular reactive oxygen species (ROS) and malondialdehyde (MDA) productions were increased by FFA and HF-diet, but supplementation with CLW significantly decreased these levels. CLW treatment ameliorated antioxidant activities that were suppressed by exposure to the FFA and HF-diet. Cluster of differentiation 36 (CD36) and fatty acid transport proteins (FATP2 and FATP5) were increased in HF-diet groups, while CLW suppressed their expression levels. Moreover, sterol regulatory element-binding protein-1c (SREBP-1c), acetyl-coenzyme A carboxylase (ACC), and fatty acid synthase (FAS) expression levels were down-regulated in the CLW groups compared to HF-diet groups. On the other hand, 5 ' adenosine monophosphate-activated protein kinase (AMPK), Peroxisome proliferator-activated receptor alpha (PPAR-alpha), and carnitine palmitoyltransferase 1 (CPT-1) expressions were up-regulated in the CLW groups. HF-diet fed mice showed high hepatic triglycerides (TG) content compared to the normal diet mice. However, the administration of CLW restored the hepatic TG level, indicating an inhibitory effect against lipid accumulation by CLW. These results suggest that CLW could be a potentially useful agent for the prevention of NAFLD through modulating fatty acid uptake.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Oxidative Stress in Non-Alcoholic Fatty Liver Disease
    Smirne, Carlo
    Croce, Eleonora
    Di Benedetto, Davide
    Cantaluppi, Vincenzo
    Comi, Cristoforo
    Sainaghi, Pier Paolo
    Minisini, Rosalba
    Grossini, Elena
    Pirisi, Mario
    LIVERS, 2022, 2 (01): : 30 - 76
  • [42] Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial
    Barghchi, Hanieh
    Milkarizi, Narges
    Belyani, Saba
    Norouzian Ostad, Andisheh
    Askari, Vahid Reza
    Rajabzadeh, Farnood
    Goshayeshi, Ladan
    Ghelichi Kheyrabadi, Seyede Yegane
    Razavidarmian, Maryam
    Dehnavi, Zahra
    Sobhani, Seyyed Reza
    Nematy, Mohsen
    NUTRITION JOURNAL, 2023, 22 (01)
  • [43] Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
    Pisonero-Vaquero, Sandra
    Gonzalez-Gallego, Javier
    Sanchez-Campos, Sonia
    Victoria Garcia-Mediavilla, Maria
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (25) : 2991 - 3012
  • [44] Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition
    Arendt, Bianca M.
    Mohammed, Saira S.
    Ma, David W. L.
    Aghdassi, Elaheh
    Salit, Irving E.
    Wong, David K. H.
    Guindi, Maha
    Sherman, Morris
    Heathcote, Elizabeth J.
    Allard, Johane P.
    CURRENT HIV RESEARCH, 2011, 9 (02) : 128 - 135
  • [45] Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
    Butterworth, Roger F.
    Canbay, Ali
    DIGESTIVE DISEASES, 2019, 37 (01) : 63 - 68
  • [46] Non-alcoholic fatty liver disease and liver transplantation
    Khan, Reenam S.
    Newsome, Philip N.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1208 - 1223
  • [47] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
  • [48] Liver transplantation and non-alcoholic fatty liver disease
    Petros Zezos
    Eberhard L Renner
    World Journal of Gastroenterology, 2014, (42) : 15532 - 15538
  • [49] Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
    Wu, Dongqing
    Zhu, Huaqing
    Wang, Hua
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [50] The epidemiology of non-alcoholic fatty liver disease
    Bellentani, Stefano
    LIVER INTERNATIONAL, 2017, 37 : 81 - 84